Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05746039 · ClinicalTrials.gov registry record · Phase 1
Feasibility of Semaglutide in Advanced Lung Disease
A Phase 1 study of Obesity and Chronic Obstructive Pulmonary Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05746039: Recruiting Phase 1 study of Obesity and Chronic Obstructive Pulmonary Disease, sponsored by University of Pennsylvania.
NCT05746039 is a Phase 1 study of Obesity and Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 8 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05746039, a Phase 1 study of Obesity and Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
Primary Outcome
The proportion of participants who either reach a target semaglutide dose of 1.0 mg/week or who achieve target weight.
Conditions Studied
Interventions
- DRUG Semaglutide Pen Injector
Study Locations (1)
Pennsylvania
- University of Pennsylvania Perelman School of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2025-12-28 |
| Phase | Phase 1 |
What NCT05746039 shows while recruiting
NCT05746039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Semaglutide Pen Injector is the first listed.
NCT05746039 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05746039 about?
NCT05746039 is a clinical study titled "Feasibility of Semaglutide in Advanced Lung Disease". The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semagluti...
What is the current status of trial NCT05746039?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-01-29. Estimated completion is 2025-12-28.
What conditions does trial NCT05746039 study?
This clinical trial studies the following conditions: Obesity, Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Interstitial Lung Disease, Sarcoidosis, Pulmonary.
What interventions are being tested in trial NCT05746039?
The interventions under investigation include: Semaglutide Pen Injector (DRUG).
Who is sponsoring clinical trial NCT05746039?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05746039 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05746039's enrollment target sits among peer trials
8 1038th of 1053 higher than 10 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI